IT-Nov 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. IT-Nov 100 is effective against infections caused by dermatophytes, yeasts, and molds, including onychomycosis, histoplasmosis, blastomycosis, aspergillosis, and candidiasis. The capsule formulation allows for oral administration with good bioavailability when taken with food. IT-Nov 100 should be prescribed based on susceptibility and clinical judgment, with dosage and duration tailored to the specific infection and patient response. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be reviewed due to itraconazole’s inhibition of CYP3A4 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Monitoring liver function tests during prolonged therapy is recommended to detect hepatotoxicity early. IT-Nov 100 Capsule provides an effective antifungal option for managing challenging fungal infections under medical supervision.